Skip to content

Retrospective analysis of the effect of different muscle relaxants on the prognosis of tumors

Retrospective analysis of the effect of different muscle relaxants on the prognosis of tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900023305
Enrollment
Unknown
Registered
2019-05-21
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The effect of different muscle relaxants on the prognosis of tumors

Interventions

1+2:Cisatracurium + Rocuronium

Sponsors

Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Age 18-75 years; ASA I-III grade; Initial cancer patients without anti-cancer therapy such as radiotherapy and chemotherapy; Preoperative platelet count, neutrophils, lymphocytes, monocytes reflect normal baseline values; Postoperative pathology confirmed cancer, no distant metastasis.

Exclusion criteria

Exclusion criteria: Preoperative renal, brain, cardiopulmonary dysfunction; Preoperative moderate to severe anemia (hemoglobin < 90g/L); Preoperative infectious diseases or other systemic inflammation; Combined with other bone marrow, blood or autoimmune diseases, multiple tumors; Has a history of malignant tumors or combined with concurrent malignant tumors; Patients requiring reoperation within one week after the first operation due to postoperative complications; Patients with unresected tumors due to infiltration of tumor cells into surrounding tissues; Palliative surgical treatment; Other non-primary diseases patients with malignant tumors who underwent resection of the site; Patients who received hospitalization before the first chemotherapy due to complications after surgery.

Design outcomes

Primary

MeasureTime frame
Postoperative NLR;Postoperative PLR;Return to intended oncologic therapy;Three-year survival or mortality after surgery;Postoperative hospital stay;Preoperative general information (gender; age; ASA, etc.);Types and dosage of intraoperative muscle relaxants;The length of operation; the length of anesthesia.;

Secondary

MeasureTime frame
PACU duration;Length of stay;Postoperative transfer to ICU;Postoperative complications;Death in hospital;

Countries

China

Contacts

Public ContactLin Yun

Tongji Medical College of Huazhong University of Science and Technology

frank0130@126.com+86 13986288403

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026